The 2022 North America Conference on Lung Cancer was held from September 23 to 25 in Chicago, Illinois. In this podcast, Xiuning Le, MD, PhD, discusses research highlights from the meeting in non-small cell lung cancer (NSCLC).
A follow-up on the phase 3 ADAURA clinical trial, which was studying whether the targeted therapy drug osimertinib (Tagrisso) given after surgery helped prevent recurrence, including brain metastases, in people with NSCLC with a classical epidermal growth factor receptor (EGFR) mutation. [3:28]
An updated analysis of 2 studies (WU-KONG1 and WU-KONG2) observing whether the targeted therapy drug sunvozertinib (DZD9008) helped shrink the tumors in people with NSCLC with an EGFR exon 20 insertion mutation who previously received chemotherapy. [6:57]
Results from the phase 2 VISION clinical trial, which was studying whether the targeted therapy drug tepotinib (Tepmetko) helped shrink the tumors in people with NSCLC with alterations of the mesenchymal epithelial transition (MET) gene. [10:38]
Dr. Le is an assistant professor in the Department of Thoracic/Head and Neck Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas. Dr. Le is also a 2022 Lung Cancer Advisory Panelist on the Cancer.Net Editorial Board.
Disclosure information for Dr. Le can be found in her individual biography linked to in the paragraph above.
Was this podcast useful? Please subscribe, rate, and review Cancer.Net Podcasts wherever you listen to podcasts. This prerecorded podcast can be listened to online or downloaded to your computer. A transcript is also available. For more information, visit the Cancer.Net podcast page.
Cancer.Net podcasts are edited for length and content.